• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up2.00% Nasdaq Up1.66%

    Regeneron Pharmaceuticals, Inc. (REGN)

    379.01 Up 11.77(3.20%) Feb 12, 4:00PM EST
    |After Hours : 379.09 Up 0.08 (0.02%) Feb 12, 5:04PM EST
    ProfileGet Profile for:
    Regeneron Pharmaceuticals, Inc.
    777 Old Saw Mill River Road
    Tarrytown, NY 10591
    United States - Map
    Phone: 914-847-7000
    Website: http://www.regeneron.com

    Index Membership:N/A
    Full Time Employees:N/A

    Business Summary 

    Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration and diabetic macular edema, as well as macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of low-density lipoprotein cholesterol; and ARCALYST for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrens. The company is also developing trap-based clinical product EYLEA for the treatment of Neovascular Glaucoma; antibody-based clinical products comprising Praluent, Sarilumab, Dupilumab, REGN2810, REGN2176-3, Fasinumab, REGN2222, Evinacumab, REGN1033, REGN1908-1909, REGN1979, and Nesvacumab/aflibercept; and ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer. It has collaborations with Sanofi, Bayer HealthCare, and Mitsubishi Tanabe Pharma Corporation for the development of antibody-based clinical based products. The company was founded in 1988 and is headquartered in Tarrytown, New York.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Regeneron Pharmaceuticals, Inc.

    Corporate Governance 
    Regeneron Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 10. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 10; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Leonard S. Schleifer M.D., Ph.D., 63
    Co-Founder, Chief Exec. Officer, Pres, Exec. Director and Ex-Officio Member of Technology Committee
    Dr. Alfred G. Gilman M.D., Ph.D., 74
    Co-Founder, Independent Director, Chairman of Corp. Governance & Compliance Committee and Member of Technology Committee
    Mr. Robert E. Landry Jr., 52
    Chief Financial Officer and Sr. VP of Fin.
    Mr. George D. Yancopoulos M.D., Ph.D., 56
    Chief Scientific Officer, Director, Member of Technology Committee and Pres of Regeneron Research Laboratories
    Dr. Neil Stahl Ph.D., 59
    Exec. VP of R&D
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders